411 related articles for article (PubMed ID: 34191622)
21. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
Harris WS; Dayspring TD; Moran TJ
Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
[TBL] [Abstract][Full Text] [Related]
22. Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease: From fish to pharmaceuticals.
Bosomworth NJ
Can Fam Physician; 2023 Jul; 69(7):459-468. PubMed ID: 37452000
[TBL] [Abstract][Full Text] [Related]
23. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
24. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
[TBL] [Abstract][Full Text] [Related]
25. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
Dixon DL
Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
[TBL] [Abstract][Full Text] [Related]
26. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF
Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245
[TBL] [Abstract][Full Text] [Related]
27. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
28. Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason RP; Sherratt SCR; Eckel RH
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101681. PubMed ID: 35739003
[TBL] [Abstract][Full Text] [Related]
29. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.
Brunton S; Collins N
Curr Med Res Opin; 2007 May; 23(5):1139-45. PubMed ID: 17519081
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risk reduction with icosapent ethyl.
Patel PN; Patel SM; Bhatt DL
Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
[TBL] [Abstract][Full Text] [Related]
31. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar.
Weinberg RL; Brook RD; Rubenfire M; Eagle KA
J Am Coll Cardiol; 2021 Feb; 77(5):593-608. PubMed ID: 33538258
[TBL] [Abstract][Full Text] [Related]
33. Effect of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials.
Huang L; Zhang F; Xu P; Zhou Y; Liu Y; Zhang H; Tan X; Ge X; Xu Y; Guo M; Long Y
Adv Nutr; 2023 Jul; 14(4):629-636. PubMed ID: 37121469
[TBL] [Abstract][Full Text] [Related]
34. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
35. A Response to: Letter to the Editor Regarding "Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review".
Hilleman DE; Wiggins BS; Bottorff MB
Adv Ther; 2020 Sep; 37(9):4046-4048. PubMed ID: 32647913
[No Abstract] [Full Text] [Related]
36. Cardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo SH; Han SH; Kim SH; Eckel RH; Koh KK
Atherosclerosis; 2021 Apr; 322():15-23. PubMed ID: 33706079
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Kwak SM; Myung SK; Lee YJ; Seo HG;
Arch Intern Med; 2012 May; 172(9):686-94. PubMed ID: 22493407
[TBL] [Abstract][Full Text] [Related]
38. Omega-3 (
Djuricic I; Calder PC
Nutrients; 2024 Mar; 16(7):. PubMed ID: 38612996
[TBL] [Abstract][Full Text] [Related]
39. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Weintraub HS
Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
[TBL] [Abstract][Full Text] [Related]
40. Potential benefits of icosapent ethyl on the lipid profile: case studies.
Hilleman DE; Malesker MA
Clin Med Insights Cardiol; 2014; 8():13-5. PubMed ID: 24516343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
